What it's for (Indications)
- This medication, containing polymyxin B and lignocaine, is indicated for the topical treatment of acute and chronic otitis externa, commonly known as 'swimmer's ear.
- ' It is specifically formulated to address bacterial infections of the external auditory canal, particularly those caused by susceptible Gram-negative organisms such as *Pseudomonas aeruginosa*.
- The lignocaine component provides rapid local anesthetic action, alleviating associated pain and discomfort, which is a common and often severe symptom of otitis externa.
- This combination is typically prescribed when both bacterial infection and significant pain are present, following a thorough medical examination to confirm the diagnosis and rule out contraindications, most notably a perforated tympanic membrane.
- It is crucial to note that this preparation is for external ear use only and is not intended for ophthalmic or systemic administration.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The typical dosage involves instilling a specific number of drops into the affected ear canal, usually three to four drops, two to three times daily. The exact regimen, including the number of drops, frequency, and duration of treatment, must be strictly adhered to as prescribed by a qualified healthcare professional. Before administration, it is often recommended to warm the solution by holding the bottle in the hand for a few minutes. This warming helps to prevent vestibular stimulation and associated dizziness that can occur from introducing cold liquid into the ear canal. The patient should lie with the affected ear upward for several minutes after instillation to allow the drops to penetrate adequately and ensure maximum contact with the infected area. Treatment duration generally ranges from 7 to 10 days, or as determined by the physician based on clinical response and resolution of symptoms. It is imperative not to discontinue treatment prematurely, even if symptoms improve, to ensure complete eradication of the infection and prevent recurrence or development of antibiotic resistance. |
Safety & Warnings
Common Side Effects
- As with any medication, polymyxin B and lignocaine ear drops can cause adverse reactions, though they are generally well-tolerated when used as directed.
- Common side effects are typically localized to the application site and may include mild irritation, itching, stinging, burning sensation, or discomfort within the external ear canal.
- These local reactions are usually transient and resolve with continued use or discontinuation.
- Hypersensitivity reactions, while rare, can manifest as a localized rash, pruritus, erythema, or swelling, and necessitate immediate discontinuation of the product and medical evaluation.
- Prolonged or excessive use, particularly in individuals with a compromised tympanic membrane, carries a theoretical risk of ototoxicity, which could manifest as hearing impairment (e.
- g.
- , tinnitus, hearing loss) or vestibular disturbances (e.
- g.
- , dizziness, vertigo), although this is more frequently associated with systemic polymyxin B administration.
- Additionally, the disruption of normal flora by the antibiotic component can, in some instances, lead to superinfection with resistant bacteria or fungi, requiring further medical evaluation and potentially alternative therapeutic approaches.
- Patients should report any persistent or worsening symptoms, or the development of new adverse effects, to their prescribing physician promptly.
Serious Warnings
- Black Box Warning: **Serious Warnings Regarding Ototoxicity and Perforated Tympanic Membrane** While systemic polymyxin B formulations are associated with formal FDA Black Box Warnings concerning nephrotoxicity and neurotoxicity, including potential neuromuscular blockade, these severe systemic risks are generally not associated with the topical application of polymyxin B in ear drops due to minimal systemic absorption when the tympanic membrane is intact. However, a significant and critical warning specifically pertinent to otic formulations containing polymyxin B is the profound risk of ototoxicity when the tympanic membrane is perforated. In such instances, the antibiotic can directly enter the middle ear and subsequently the inner ear (cochlea and vestibule), leading to irreversible damage to the delicate sensory hair cells and neural structures. This can result in permanent sensorineural hearing loss, persistent tinnitus, and/or balance disturbances (vertigo). Therefore, a definitive diagnosis confirming the integrity of the tympanic membrane via thorough otoscopic examination by a qualified healthcare professional is absolutely mandatory prior to initiating therapy with this product. This medication must not be used if a perforated eardrum is suspected or confirmed. Patients should be explicitly counselled on the critical importance of this examination and the potential irreversible consequences of ototoxicity if this contraindication is overlooked, emphasizing that self-diagnosis and treatment are highly discouraged without professional medical advice.
- This combination ear drop formulation necessitates careful consideration of several warnings to ensure patient safety and optimize therapeutic outcomes.
- It is critically important to rule out a perforated tympanic membrane (eardrum) prior to initiating treatment.
- If the eardrum is perforated, the active ingredients, particularly polymyxin B, can gain access to the middle ear and inner ear, posing a significant risk of ototoxicity, which could lead to irreversible sensorineural hearing loss or other vestibular damage.
- The product should not be used for viral or fungal infections of the ear, as it is specifically designed for bacterial etiologies and would be ineffective, potentially delaying appropriate treatment for the actual pathogen.
- Hypersensitivity reactions to either polymyxin B or lignocaine, or any other component of the formulation, can occur and require immediate cessation of use.
- Prolonged use of antibiotics can lead to the overgrowth of non-susceptible organisms, including fungi, necessitating re-evaluation and potentially alternative treatment strategies.
- Patients should be advised to avoid contact with the eyes; if accidental exposure occurs, rinse thoroughly with copious amounts of water.
- If symptoms do not improve within a few days of initiating therapy, or if they worsen, a re-assessment by a healthcare professional is mandatory to rule out other underlying conditions, adjust therapy, or identify potential superinfections.
How it Works (Mechanism of Action)
The therapeutic efficacy of this ear drop formulation stems from the synergistic actions of its two primary components: polymyxin B and lignocaine. Polymyxin B, a cyclic polypeptide antibiotic, exerts its potent bactericidal effects primarily against Gram-negative bacteria, including highly resistant strains such as *Pseudomonas aeruginosa*, a common pathogen in otitis externa. Its mechanism involves disrupting the integrity of the bacterial cell membrane. Specifically, polymyxin B, being a cationic detergent, binds electrostatically to the negatively charged phospholipids in the outer and inner membranes of bacterial cells. This binding displaces essential divalent cations (e.g., magnesium, calcium) that stabilize the membrane, thereby increasing the permeability of the bacterial membrane. This leads to the rapid leakage of essential intracellular components, such as nucleotides, amino acids, and ions, ultimately resulting in bacterial cell death. Lignocaine (lidocaine), on the other hand, functions as a local anesthetic. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of nerve impulses, particularly by blocking voltage-gated sodium channels. This action prevents the transmission of pain signals from the peripheral nerve endings in the ear to the central nervous system, providing rapid and effective symptomatic relief from the pain, stinging, and discomfort associated with otitis externa. Together, these agents combat the bacterial infection and mitigate its primary symptom.
Commercial Brands (Alternatives)
No other brands found for this formula.